共 50 条
Key Molecular Drivers of Chronic Lymphocytic Leukemia
被引:13
|作者:
Alsagaby, Suliman A.
[1
,2
]
Brennan, Paul
[2
]
Pepper, Chris
[2
]
机构:
[1] Majmaah Univ, Coll Sci, Dept Lab Med, King Fahd St,POB 1712, Al Zuli 11932, Riyadh Region, Saudi Arabia
[2] Cardiff Univ, Sch Med, Inst Canc & Genet, Cardiff, S Glam, Wales
来源:
关键词:
CLL;
Molecular drivers;
Pathogenicity;
Prognosis;
Therapy;
NF-KAPPA-B;
VARIABLE-REGION MUTATIONS;
TREATMENT-FREE SURVIVAL;
CELL-RECEPTOR;
CD38;
EXPRESSION;
THERAPEUTIC TARGET;
SF3B1;
MUTATIONS;
SOLUBLE CD23;
DISEASE PROGRESSION;
PROGNOSTIC MARKER;
D O I:
10.1016/j.clml.2016.08.008
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Chronic lymphocytic leukemia (CLL) is an adult neoplastic disease of B cells characterized by variable clinical outcomes. Although some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for theraphy. In the past decade, significant advances have been made in our understanding of the molecular drivers that affect the natural pathology of CLL. The present review describes what is known about these key molecules in the context of their role in tumor pathogenicity, prognosis, and therapy. Crown Copyright (C) 2016 Published by Elsevier Inc. All rights reserved.
引用
下载
收藏
页码:593 / 606
页数:14
相关论文